KYIV, Ukraine – Enamine, a leading chemistry and R&D services company, today announced its key role as a synthetic chemistry contributor to a pioneering open-science initiative. This collaborative effort led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate.
Enamine’s advanced chemistry platform delivered over 2,000 new compounds during the early stages of the program, driving the discovery of the pre-clinical candidate known as ASAP-0017445.
